État des lieux et perspectives de la protonthérapie

Doyen, J.; Bondiau, Pierre‐Yves; Bénézery, Karen; Chand, Marie-Eve; Thariat, Juliette; Leysalle, A.; Gérard, Jean-Pierre; Habrand, Jean‐Louis; Hannoun-Lévi, J.-M.

doi:10.1016/j.canrad.2014.12.010

Cited by 5 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This feature of proton beams enables the radiologist to deposit a high physical dose into a deep-seated tumor [1]. Proton therapy has been widely utilized for tumor therapy [2]. Recently, precise evaluation of relative biological effectiveness (RBE; the ratio of the absorbed dose of the particle beam to the absorbed dose of 250 kV X-rays or 60 Co gamma-rays required to produce the same biological effect) has been reported for several positions in SOBP of passive scattering proton beams [3–7] and scanning proton pencil beams [8].…”

Section: Introductionmentioning

confidence: 99%

A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam

et al. 2016

View full text Add to dashboard Cite

The effect of 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd) on proton-induced cell death was evaluated in human lung carcinoma cell line A549 and Chinese hamster fibroblast cell line V79 to enhance relative biological effectiveness (RBE) within the spread-out Bragg peak (SOBP) of proton beams. Treatment with ECyd significantly enhanced the proton-induced loss of clonogenicity and increased senescence at the center, but not at the distal edge of SOBP. The p53-binding protein 1 foci formation assay showed that ECyd decelerated the rate of DNA double-strand break (DSB) repair at the center, but not the distal region of SOBP, suggesting that the ECyd-induced enhancement of proton-induced cell death is partially associated with the inhibition of DSB repair. This study demonstrated that ECyd enhances proton-induced cell killing at all positions of SOBP, except for the distal region and minimizes the site-dependent differences in RBE within SOBP. Thus, ECyd is a unique radiosensitizer for proton therapy that may be useful because it levels the biological dose within SOBP, which improves tumor control and reduces the risk of adverse effects at the distal edge of SOBP.

show abstract